The price of biohaven shares does not subvalrate the potential of pipes, according to RBC Capital

RBC capital He states that the notes published by the Chmp of the European Medicines Agency indicated that Biohaven (Bhvn) He had withdrawn the application for troriluzol in spinocerebelar ataxia. The sentiment of the investors has been more bassist lately, with the majority believing that SCA approval in the United States is essential to help actions to recover, says that the firm, who believes that this news “is” extra pressure “and explains the movement of actions. However, he also believes that the EMA has been a stricter regulator of rare afternoon diseases compared to the FDA, which could limit readings. Although “a little disadvantage is required in the news” of the 6%-7%rank, the firm still believes that the current price of the shares undervaluing the United States approval in SCA and the opportunities for biohaven pipes, adds the analyst, who has a higher rating and $ 61. Price target about actions.

Published first Thefly -The definitive source for real -time financial news and moving in the market. Try now >>

Check out the best stocks recommended by analysts >>

More information about BHVN:

Resignation and disseminationReport a problem